Stephanie A Moquin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6556987/publications.pdf

Version: 2024-02-01

759233 1199594 2,942 12 12 12 citations h-index g-index papers 13 13 13 3444 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature, 2013, 496, 469-476.	27.8	961
2	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature, 2011, 480, 336-343.	27.8	794
3	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. Immunity, 2013, 39, 245-258.	14.3	332
4	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. Cell, 2015, 161, 1280-1292.	28.9	305
5	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. Science, 2013, 340, 751-756.	12.6	213
6	PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4. Journal of Virology, 2012, 86, 4394-4403.	3.4	109
7	The Epstein-Barr Virus Episome Maneuvers between Nuclear Chromatin Compartments during Reactivation. Journal of Virology, 2018, 92, .	3.4	46
8	NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models. Science Translational Medicine, 2021, 13, .	12.4	43
9	Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies. Structure, 2016, 24, 1346-1357.	3.3	35
10	Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps. Journal of Biological Chemistry, 2017, 292, 13284-13295.	3.4	35
11	Outer Domain of HIV-1 gp120: Antigenic Optimization, Structural Malleability, and Crystal Structure with Antibody VRC-PG04. Journal of Virology, 2013, 87, 2294-2306.	3.4	34
12	PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter. Virology, 2017, 507, 220-230.	2.4	33